目的 了解解放军总医院抗震颤麻痹药物的应用情况与用药趋势。方法 采用世界卫生组织（WHO）推荐的以限定日剂量（DDD）为指标的分析方法，对2015-2017年解放军总医院抗震颤麻痹药物的销售金额、用药频度（DDDs）、日均费用（DDC）及排序比（B/A）等进行统计分析。结果 普拉克索、多巴丝肼和恩他卡朋的用药金额始终处于前3位，普拉克索的用药金额逐渐上升，卡比多巴/左旋多巴的用药金额逐渐下降；DDDs排序列前2位的是多巴丝肼和司来吉兰，多巴丝肼的DDDs逐年上升，一直处于第1位；2015-2016年各种抗震颤麻痹药物的DDC较为稳定，2016-2017年各种抗震颤麻痹药物的DDC开始略有下降；除普拉克索和恩他卡朋的B/A始终小于1.00，其他抗震颤麻痹药物的B/A均在1.00以上波动。结论 解放军总医院抗震颤麻痹药物的使用较为合理，其中多巴丝肼、普拉克索和司来吉兰具有很好的市场前景。

Objective To investigate the utilization and tendency of antiparkinsonian drugs in PLA General Hospital. Methods The consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of antiparkinsonian drugs in PLA General Hospital from 2015 to 2017 were analyzed retrospectively by defined daily doses (DDD) recommended by WHO. Results Sale amounts of pramipexole, levodopa, and benserazide hydrochlo-ride, and entacapone were always in the top three. Consumption sum of pramipexole was increasing during three years, while consumption sum of carbidopa/levodopa was decreasing. DDDs of levodopa and benserazide hydrochlo-ride and selegiline were ranked the top two. DDDs of levodopa and benserazide hydrochlo-ride increased year by year, and keep the first from 2015 to 2017. DDC of various antiparkinsonian drugs was relatively stable from 2015 to 2016, and DDC of various antiparkinsonian drugs began to decline slightly from 2016 to 2017. B/A of pramipexole and entacapone were always less than 1.00, while B/A of other antiparkinsonian drugs fluctuated above 1.00. Conclusion The application of antiparkinsonian drugs in PLA General Hospital is more reasonable. At present, levodopa and benserazide hydrochlo-ride, pramipexole, and selegiline have good market prospects.

国家"重大新药创制"科技重大专项资助项目（2018ZX09201013）